Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

22 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The long and winding road to biomarkers for immunotherapy: a retrospective analysis of samples from patients with triple-negative breast cancer treated with pembrolizumab.
Buisseret L, Bareche Y, Venet D, Girard E, Gombos A, Emonts P, Majjaj S, Rouas G, Serra M, Debien V, Agostinetto E, Garaud S, Willard-Gallo K, Larsimont D, Stagg J, Rothé F, Sotiriou C. Buisseret L, et al. Among authors: debien v. ESMO Open. 2024 May 3;9(5):102964. doi: 10.1016/j.esmoop.2024.102964. Online ahead of print. ESMO Open. 2024. PMID: 38703428 Free PMC article.
The Impact of Initial Tumor Response on Survival Outcomes of Patients With HER2-Positive Advanced Breast Cancer Treated With Docetaxel, Trastuzumab, and Pertuzumab: An Exploratory Analysis of the CLEOPATRA Trial.
Debien V, Agostinetto E, Bruzzone M, Ceppi M, Martins-Branco D, Molinelli C, Jacobs F, Nader-Marta G, Lambertini M, de Azambuja E. Debien V, et al. Clin Breast Cancer. 2024 Feb 21:S1526-8209(24)00050-8. doi: 10.1016/j.clbc.2024.02.012. Online ahead of print. Clin Breast Cancer. 2024. PMID: 38514306
Author Correction: Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I/II trial.
Buisseret L, Loirat D, Aftimos P, Maurer C, Punie K, Debien V, Kristanto P, Eiger D, Goncalves A, Ghiringhelli F, Taylor D, Clatot F, Van den Mooter T, Ferrero JM, Bonnefoi H, Canon JL, Duhoux FP, Mansi L, Poncin R, Barthélémy P, Isambert N, Denis Z, Catteau X, Salgado R, Agostinetto E, de Azambuja E, Rothé F, Craciun L, Venet D, Romano E, Stagg J, Paesmans M, Larsimont D, Sotiriou C, Ignatiadis M, Piccart-Gebhart M. Buisseret L, et al. Among authors: debien v. Nat Commun. 2023 Dec 12;14(1):8223. doi: 10.1038/s41467-023-44071-8. Nat Commun. 2023. PMID: 38086864 Free PMC article. No abstract available.
The impact of erythropoiesis-stimulating agents administration concomitantly with adjuvant anti-HER2 treatments on the outcomes of patients with early breast cancer: a sub-analysis of the ALTTO study.
Martins-Branco D, Kassapian M, Debien V, Caparica R, Eiger D, Dafni U, Andriakopoulou C, El-Abed S, Ellard SL, Izquierdo M, Vicente M, Chumsri S, Piccart-Gebhart M, Moreno-Aspitia A, Knop AS, Lombard J, de Azambuja E. Martins-Branco D, et al. Among authors: debien v. Breast Cancer Res Treat. 2024 Feb;203(3):497-509. doi: 10.1007/s10549-023-07159-9. Epub 2023 Nov 8. Breast Cancer Res Treat. 2024. PMID: 37938495 Free PMC article.
Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I/II trial.
Buisseret L, Loirat D, Aftimos P, Maurer C, Punie K, Debien V, Kristanto P, Eiger D, Goncalves A, Ghiringhelli F, Taylor D, Clatot F, Van den Mooter T, Ferrero JM, Bonnefoi H, Canon JL, Duhoux FP, Mansi L, Poncin R, Barthélémy P, Isambert N, Denis Z, Catteau X, Salgado R, Agostinetto E, de Azambuja E, Rothé F, Craciun L, Venet D, Romano E, Stagg J, Paesmans M, Larsimont D, Sotiriou C, Ignatiadis M, Piccart-Gebhart M. Buisseret L, et al. Among authors: debien v. Nat Commun. 2023 Nov 2;14(1):7018. doi: 10.1038/s41467-023-42744-y. Nat Commun. 2023. PMID: 37919269 Free PMC article. Clinical Trial.
Real-world clinical outcomes of patients with stage I HER2-positive breast cancer treated with adjuvant paclitaxel and trastuzumab.
Debien V, Marta GN, Agostinetto E, Sirico M, Jacobs F, Molinelli C, Moreau M, Paesmans M, De Giorgi U, Santoro A, Taylor D, Duhoux FP, Botticelli A, Barchiesi G, Speranza I, Lambertini M, Wildiers H, Azambuja E, Piccart M. Debien V, et al. Crit Rev Oncol Hematol. 2023 Oct;190:104089. doi: 10.1016/j.critrevonc.2023.104089. Epub 2023 Aug 9. Crit Rev Oncol Hematol. 2023. PMID: 37562696 Review.
Outcome of adrenocortical carcinoma patients included in early phase clinical trials: Results from the French network ENDOCAN-COMETE.
Hescot S, Debien V, Hadoux J, Drui D, Haissaguerre M, de la Fouchardiere C, Vezzosi D, Do Cao C, Libé R, Le Tourneau C, Baudin E, Massard C, du Rusquec P; from the French ENDOCAN-COMETE network. Hescot S, et al. Among authors: debien v. Eur J Cancer. 2023 Aug;189:112917. doi: 10.1016/j.ejca.2023.05.006. Epub 2023 May 16. Eur J Cancer. 2023. PMID: 37277263 Clinical Trial.
22 results